<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552873</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.189</org_study_id>
    <nct_id>NCT04552873</nct_id>
  </id_info>
  <brief_title>Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage</brief_title>
  <acronym>NAT-URE</acronym>
  <official_title>Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyponatremia is defined as a plasma sodium concentration below 135 mmol / L. This is a common&#xD;
      occurrence (20-50%) during subarachnoid hemorrhage (SAH). Its appearance is often associated&#xD;
      with vasospasm. It is associated with an increase in morbidity and mortality linked to&#xD;
      induced neurological disorders. Hyponatremia is caused by two etiologies: the syndrome of&#xD;
      inappropriate secretion of anti-diuretic hormone (SIADH), and the cerebral salt wasting&#xD;
      syndrome, CSWS. Theoretically, these two entities are differentiated by the patient's&#xD;
      volemia; in practice, this parameter is difficult to measure. In addition, the correction of&#xD;
      hyponatremia is diametrically opposed according to its mechanism: water restriction in the&#xD;
      case of SIADH, sodium intake in the event of CSWS. Urea is offered as a second-line treatment&#xD;
      in the event of treatment failure to correct hyponatremia. However, the efficacy of this&#xD;
      treatment is based on small, observational, retrospective studies. Moreover, the mechanism of&#xD;
      action of urea remains poorly understood: it could be a hyperosmolar effect or passive renal&#xD;
      reabsorption of sodium.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparative study in 2 parallel arms, monocentric, randomized, double blind.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the effectiveness of urea therapy in correcting persistent hyponatremia despite adequate management during subarachnoid hemorrhage</measure>
    <time_frame>5 DAYS</time_frame>
    <description>Change in blood serum in mmol / L measured before initiation of treatment and on the day of discontinuation of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Hyponatremia</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>SIADH</condition>
  <arm_group>
    <arm_group_label>EXPERIMENTAL GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the control group will be treated during 5 days by ergytonyl dose per administration : 5mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urea</intervention_name>
    <description>the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)&#xD;
If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.&#xD;
If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered.</description>
    <arm_group_label>EXPERIMENTAL GROUP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>the control group will be treated during 5 days by ergytonyl dose per administration : 5mL</description>
    <arm_group_label>CONTROL GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged at least 18 years old&#xD;
&#xD;
          -  Non-traumatic HSA&#xD;
&#xD;
          -  Hyponatremia defined by a natremia less than 135 mmol / L and a high natriuresis,&#xD;
             greater than 250 mmol / L despite well-managed saline intakes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe cardiac decompensation (LVEF &lt;30%)&#xD;
&#xD;
          -  Severe hepatic cirrhosis (PT &lt;30%, ascites), known severe renal failure (GFR &lt;30mL /&#xD;
             min / 1.73m²)&#xD;
&#xD;
          -  Blood urea&gt; 25 mmol / L in the basal state&#xD;
&#xD;
          -  Osmotherapy and diuretics in the last 48 hours&#xD;
&#xD;
          -  Ongoing treatment with systemic corticosteroids&#xD;
&#xD;
          -  Persons referred to in Articles L1121-5 to L1121-8 of the CSP corresponding to all&#xD;
             protected persons: pregnant woman, parturient, nursing mother, person deprived of&#xD;
             liberty by judicial or administrative decision, person subject to a legal protection&#xD;
             measure.&#xD;
&#xD;
          -  Patient not affiliated to a social security scheme&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of ergytonyl&#xD;
&#xD;
          -  Contraindications to ergytonyl: taking curative anticoagulants, previously known and&#xD;
             treated diabetic patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perrine BOUCHEIX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Perrine BOUCHEIX, MD</last_name>
    <phone>04 76 76 67 29</phone>
    <email>pboucheix@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anaïs ADOLLE</last_name>
    <phone>04 76 76 67 29</phone>
    <email>arcpar@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perrine BOUCHEIX, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Anaïs ADOLLE</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hall A, O'Kane R. The Extracranial Consequences of Subarachnoid Hemorrhage. World Neurosurg. 2018 Jan;109:381-392. doi: 10.1016/j.wneu.2017.10.016. Epub 2017 Oct 16. Review.</citation>
    <PMID>29051110</PMID>
  </reference>
  <reference>
    <citation>Mapa B, Taylor BE, Appelboom G, Bruce EM, Claassen J, Connolly ES Jr. Impact of Hyponatremia on Morbidity, Mortality, and Complications After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. World Neurosurg. 2016 Jan;85:305-14. doi: 10.1016/j.wneu.2015.08.054. Epub 2015 Sep 7. Review.</citation>
    <PMID>26361321</PMID>
  </reference>
  <reference>
    <citation>Hannon MJ, Behan LA, O'Brien MM, Tormey W, Ball SG, Javadpour M, Sherlock M, Thompson CJ. Hyponatremia following mild/moderate subarachnoid hemorrhage is due to SIAD and glucocorticoid deficiency and not cerebral salt wasting. J Clin Endocrinol Metab. 2014 Jan;99(1):291-8. doi: 10.1210/jc.2013-3032. Epub 2013 Dec 20. Erratum in: J Clin Endocrinol Metab. 2014 Mar;99(3):1096. Javadpur, M [corrected to Javadpour, M].</citation>
    <PMID>24248182</PMID>
  </reference>
  <reference>
    <citation>Nakajima H, Okada H, Hirose K, Murakami T, Shiotsu Y, Kadono M, Inoue M, Hasegawa G. Cerebral Salt-wasting Syndrome and Inappropriate Antidiuretic Hormone Syndrome after Subarachnoid Hemorrhaging. Intern Med. 2017;56(6):677-680. doi: 10.2169/internalmedicine.56.6843. Epub 2017 Mar 17.</citation>
    <PMID>28321069</PMID>
  </reference>
  <reference>
    <citation>Hoorn EJ, Zietse R. Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines. J Am Soc Nephrol. 2017 May;28(5):1340-1349. doi: 10.1681/ASN.2016101139. Epub 2017 Feb 7. Review.</citation>
    <PMID>28174217</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urea</keyword>
  <keyword>copeptine</keyword>
  <keyword>hyponatremia</keyword>
  <keyword>SAH</keyword>
  <keyword>SIADH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

